Alphamab Oncology (9966) Receives a Buy from Sinolink Securities
I'm PortAI, I can summarize articles.
In a report released yesterday, from Sinolink Securities maintained a Buy rating on Alphamab Oncology, with a price target of HK$14.30.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alphamab Oncology with a HK$13.00 average price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments